| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/15/2022 | 48.15% | HC Wainwright & Co. | $6 → $2 | Maintains | Buy |
| 03/07/2022 | 270.37% | Lake Street | → $5 | Initiates Coverage On | → Buy |
| 11/23/2021 | 344.44% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 07/01/2021 | 418.52% | Northland Capital Markets | → $7 | Initiates Coverage On | → Outperform |
Biotricity Questions & Answers
The latest price target for Biotricity (NASDAQ: BTCY) was reported by HC Wainwright & Co. on July 15, 2022. The analyst firm set a price target for $2.00 expecting BTCY to rise to within 12 months (a possible 48.15% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Biotricity (NASDAQ: BTCY) was provided by HC Wainwright & Co., and Biotricity maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biotricity, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biotricity was filed on July 15, 2022 so you should expect the next rating to be made available sometime around July 15, 2023.
While ratings are subjective and will change, the latest Biotricity (BTCY) rating was a maintained with a price target of $6.00 to $2.00. The current price Biotricity (BTCY) is trading at is $1.35, which is out of the analyst's predicted range.